Want to see PMN full AI Analyst Report?
ProMIS Neurosciences (PMN) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pmn310 | Alzheimer Disease, Early Onset | Phase I | Recruiting | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Dec 16, 2024 | ― |
| Pmn310 | Healthy Participants | Phase I | Completed | A Phase 1a Study of PMN310 In Healthy Volunteers | Oct 23, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pmn310 | Phase I | Alzheimer Disease, Early Onset | Recruiting | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | Dec 16, 2024 | ― |
| Pmn310 | Phase I | Healthy Participants | Completed | A Phase 1a Study of PMN310 In Healthy Volunteers | Oct 23, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ProMIS Neurosciences Inc. (PMN) have in its pipeline
ProMIS Neurosciences PMN is currently developing the following drugs: Pmn310. These drug candidates are in various stages of clinical development as the company works toward FDA approval.